Literature DB >> 1381276

Inhibition of angiogenesis by suramin.

A Gagliardi1, H Hadd, D C Collins.   

Abstract

In this study, we have determined the ability of suramin to inhibit angiogenesis in the chick chorioallantoic membrane. Suramin alone showed significant angiostatic activity in a dose-related manner. Suramin also potentiated the activity of the angiostatic steroids, cortisol-21-phosphate, 17 alpha-hydroxyprogesterone, tetrahydrocortisol, and tetrahydrocortexolone. The presence of heparin decreased the angiostatic activity of suramin. These results suggest that suramin may decrease tumor growth by inhibiting angiogenesis. These novel findings indicate that suramin, perhaps in combination with angiostatic steroids, may be the basis for important new therapeutic approaches for diseases of neovascularization.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1381276

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

Review 1.  Multi-agent cytostatic treatment of 'low-grade' gliomas.

Authors:  M E Linskey
Journal:  Curr Oncol Rep       Date:  2000-09       Impact factor: 5.075

Review 2.  Angiogenesis: possibilities for therapeutic interventions.

Authors:  W Wynendaele; A T van Oosterom; A Pawinski; E A de Bruijn; R A Maes
Journal:  Pharm World Sci       Date:  1998-12

Review 3.  Platelet-derived growth factor in human brain tumors.

Authors:  M Kirsch; J C Wilson; P Black
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

4.  A novel angiopoietin-derived peptide displays anti-angiogenic activity and inhibits tumour-induced and retinal neovascularization.

Authors:  G M Palmer; Z Tiran; Z Zhou; M E Capozzi; W Park; C Coletta; A Pyriochou; Y Kliger; O Levy; I Borukhov; M W Dewhirst; G Rotman; J S Penn; A Papapetropoulos
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 5.  Local anti-angiogenic brain tumor therapies.

Authors:  E P Sipos; H Brem
Journal:  J Neurooncol       Date:  2000 Oct-Nov       Impact factor: 4.130

6.  Suramin treatment of human glioma xenografts; effects on tumor vasculature and oxygenation status.

Authors:  H J Bernsen; P F Rijken; J P Peters; J H Bakker; R H Boerman; P Wesseling; A J van der Kogel
Journal:  J Neurooncol       Date:  1999-09       Impact factor: 4.130

Review 7.  [Pathophysiologic significance of growth factors and new therapeutic concepts in cardiovascular disease].

Authors:  S Rosenkranz; M Böhm; A Kazlauskas
Journal:  Med Klin (Munich)       Date:  1999-09-15

Review 8.  An overview of clinical trials involving inhibitors of angiogenesis and their mechanism of action.

Authors:  W J Gradishar
Journal:  Invest New Drugs       Date:  1997       Impact factor: 3.850

9.  Suramin inhibits glioma cell proliferation in vitro and in the brain.

Authors:  S Takano; S Gately; H Engelhard; A M Tsanaclis; S Brem
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

10.  Suramin inhibits not only tumor growth and metastasis but also angiogenesis in experimental pancreatic cancer.

Authors:  Sarah Bhargava; Birgit Hotz; O Joe Hines; Howard A Reber; Heinz J Buhr; Hubert G Hotz
Journal:  J Gastrointest Surg       Date:  2007-02       Impact factor: 3.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.